别名:Acute myeloid leukemia 1 protein; CBF-alpha 2; CBFA2; Core-binding factor; alpha 2 subunit应用:WB
反应种属:Human
规格:50μl/100μl
| Description |
|---|
| CBF binds to the core site, 5′-PYGPYGGT-3′, of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits KAT6B-dependent transcriptional activation.Miyoshi H., Proc. Natl. Acad. Sci. U.S.A. 88:10431-10434(1991).Sacchi N., Genes Chromosomes Cancer 11:226-236(1994).Nucifora G., Blood 81:2728-2734(1993). |
| Specification | |
|---|---|
| Aliases | Acute myeloid leukemia 1 protein; CBF-alpha 2; CBFA2; Core-binding factor; alpha 2 subunit |
| Entrez GeneID | 861; |
| Swissprot | Q01196 |
| WB Predicted band size | 53kDa |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized non-phosphopeptide derived from human AML1 around the phosphorylation site of serine 435 (S-N-S(p)-P-T). |
| Formulation | Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Application | |
|---|---|
| WB | 1/500-1/3000 |
![]() |
Western blot analysis of extracts from HepG2 cells, treated with PMA (125ng/ml, 30mins), using AML1 (Ab-435) antibody P41742. |
![]() |
Western blot analysis of extracts from 293 cells (Lane 2) and Hela cells (Lane 3), using AML1 (Ab-435) antiobdy P41742. The lane on the left is treated with synthesized peptide. |
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的,不可用于人类或动物的临床诊断或治疗,非药用,非食用。
暂无评论
本公司的所有产品仅用于科学研究或者工业应用等非医疗目的,不可用于人类或动物的临床诊断或治疗,非药用,非食用。
中文


发表回复